Drugs / OBI-888
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03573544 | May 2018 → Apr 2022 | metastatic neoplasm | OBI Pharma, Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-11-21 | OBI Pharma, Inc | Regulatory OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer obipharma.com ↗ |
| 2018-01-17 | OBI Pharma, Inc | Regulatory OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888) obipharma.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-03-28 | OBI Pharma, Inc | OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999 obipharma.com ↗ |
| 2018-11-21 | OBI Pharma, Inc | OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer obipharma.com ↗ |
| 2018-01-17 | OBI Pharma, Inc | OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888) obipharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBI-888 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03573544 ↗ |
| Route | Intravenous | “liquid form for intravenous infusion” NCT03573544 ↗ |